Vanessa M. Beutgen

As seen in: Nature, ACS Publications

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Vanessa M.

Contact Vanessa M., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.

Claim your profile

Articles

Synergistic targeting of cancer cells through simultaneous inhibition of key metabolic enzymes - Cell Death & Differentiation

Jun 22, 2025 |

By Jan Dreute, Julia Stengel, Jonas Becher, Maximilian Pfisterer, Marek Bartkuhn, Vanessa M. Beutgen, Johannes Graumann, Michael B. Huck, Stephan Klatt, Chloe Leff, Henner F. Farin, Roland Schmitz, Thorsten Stiewe, Julia Teply-Szymanski, Jochen Wilhelm, Alfredo Cabrera-Orefice, Benardina Ndreshkjana

| Nature

Abstract As cancer cell specific rewiring of metabolic networks creates potential therapeutic opportunities, we conducted a synthetic lethal screen utilizing inhibitors of metabolic pathways. Simultaneous administration of (R)-GNE-140 and BMS-986205 (Linrodostat) preferentially halted proliferation of ovarian cancer cells, but not of their non-oncogenically transformed progenitor cells.

Open in Who Shared

BAG6 restricts pancreatic cancer progression by suppressing the release of IL33-presenting extracellular vesicles and the activation of mast cells - Cellular & Molecular Immunology

Jun 27, 2024 |

By Vanessa M. Beutgen, Johannes Graumann

| Nature

Abstract Recent studies reveal a critical role of tumor cell-released extracellular vesicles (EVs) in pancreatic cancer (PC) progression. However, driver genes that direct EV function, the EV-recipient cells, and their cellular response to EV uptake remain to be identified. Therefore, we studied the role of Bcl-2-associated-anthanogene 6 (BAG6), a regulator of EV biogenesis for cancer progression.

Open in Who Shared

Sample-Treatment with the Virucidal β-Propiolactone Does Not Preclude Analysis by Large Panel Affinity Proteomics, Including the Discovery of Biomarker Candidates

Sep 13, 2023 |

By Aditya M. Bhagwat, Silke Reinartz, Vanessa M. Beutgen, Anna Mary Steitz

| ACS Publications

Download Hi-Res ImageDownload to MS-PowerPointCite This:Anal. Chem. 2024, XXXX, XXX Terms & Conditions Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses).

Open in Who Shared View Duplicates (700)

See all 4 articles

For PR Teams

Overview

Use Cases

Capabilities

Industries

Introducing Curation Engine

Resources

Library

Commmunity

Customers

Company

Vanessa M. Beutgen

Get in touch with Vanessa M.

Actions

Is this you?

Articles

Synergistic targeting of cancer cells through simultaneous inhibition of key metabolic enzymes - Cell Death & Differentiation

BAG6 restricts pancreatic cancer progression by suppressing the release of IL33-presenting extracellular vesicles and the activation of mast cells - Cellular & Molecular Immunology

Sample-Treatment with the Virucidal β-Propiolactone Does Not Preclude Analysis by Large Panel Affinity Proteomics, Including the Discovery of Biomarker Candidates

Actions

Is this you?

Get in touch with Vanessa M.